Sponsor Letter
Huatai United Securities Co., Ltd. on Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd. Issuing Convertible Bonds to Unspecified Objects and Listing on the Main Board
Shenzhen Stock Exchange:
As the sponsor for Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd. (hereinafter referred to as the issuer or the company) in its issuance of convertible bonds to unspecified objects and listing on the main board, Huatai United Securities Co., Ltd. and its sponsoring representatives have issued this sponsor letter in accordance with the Company Law of the People's Republic of China, the Securities Law of the People's Republic of China, and relevant regulations of the China Securities Regulatory Commission and your exchange. We have acted in good faith, diligently, and responsibly, strictly following the business rules and industry self-regulatory norms established by law, and guarantee that the documents provided are true, accurate, and complete. The relevant information is reported as follows:
1. Basic Information of the Issuer
(1) Overview of the Issuer
- Issuer Name: Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd.
- Registered Address: No. 518, Yunhe Road, Xinbei District, Changzhou City
- Registration Date: April 30, 2003
- Contact Number: 0519-86020688
(2) Main Business of the Issuer
The company is a high-tech biochemical pharmaceutical enterprise integrating R&D, production, and sales, focusing on polysaccharides and protease drugs for many years, and has become a leading enterprise in this field. The main protease products include trypsinogen series, compound digestive enzyme capsules (II), aspartic acid enzyme series, and elastase, among others. The polysaccharide products mainly include heparin sodium raw materials, standard heparin preparations, and low molecular weight heparin series, with sales covering more than twenty provinces and cities across the country as well as international markets in Europe, America, and Asia. The company is also one of the few domestic pharmaceutical manufacturers with a full traceability capability from pig intestine source supply, heparin crude products, heparin raw materials, and preparations. After the production of Henan Qianmu, it is also one of the few heparin production enterprises in China that can trace back to the upstream pig breeding link, which helps further ensure high-quality and controllable source quality, effectively enhancing industry competitiveness.
(3) Main Operating and Financial Data and Indicators of the Issuer
- Consolidated Balance Sheet Main Data (Unit: Ten Thousand Yuan)
| Project | 2025.9.30 | 2024.12.31 | 2023.12.31 | 2022.12.31 |
|---|---|---|---|---|
| Total Assets | 301,548.85 | 283,044.13 | 276,608.14 | 280,593.85 |
| Total Liabilities | 25,586.25 | 31,387.06 | 29,217.29 | 37,253.02 |
| Shareholder's Equity | 275,962.60 | 251,657.06 | 247,390.85 | 243,340.83 |
| Equity Attributable to Shareholders of the Listed Company | 275,085.89 | 251,744.26 | 245,493.10 | 245,035.42 |
- Consolidated Income Statement Main Data (Unit: Ten Thousand Yuan)
| Project | 2025 (Jan-Sep) | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating Income | 121,501.50 | 152,624.28 | 181,426.89 | 230,354.78 |
| Operating Profit | 43,814.53 | 39,638.85 | 20,435.65 | 36,000.65 |
| Total Profit | 43,779.87 | 39,583.90 | 20,352.35 | 36,033.04 |
| Net Profit | 36,813.36 | 33,318.25 | 17,867.20 | 31,991.08 |
| Net Profit Attributable to Shareholders of the Listed Company | 38,322.63 | 35,603.20 | 18,186.07 | 32,341.44 |
- Consolidated Cash Flow Statement Main Data (Unit: Ten Thousand Yuan)